Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637836 | 0.89 | L3MBTL1 (0.37) | L3MBTL1CYP1A2CYP2C19KMT2ACNR1 | |
| SCHEMBL636140 | 0.87 | L3MBTL1 (0.38) | L3MBTL1KMT2ACNR1RAB9AUTS2R | |
| SCHEMBL639251 | 0.86 | L3MBTL1 (0.39) | L3MBTL1NPC1KMT2ACNR1RAB9A | |
| SCHEMBL638107 | 0.84 | L3MBTL1 (0.38) | L3MBTL1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL915655 | 0.84 | L3MBTL1 (0.40) | L3MBTL1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL639619 | 0.83 | L3MBTL1 (0.35) | L3MBTL1NPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL917739 | 0.83 | L3MBTL1 (0.37) | L3MBTL1KMT2ACNR1RAB9AHTT | |
| SCHEMBL636258 | 0.83 | L3MBTL1 (0.37) | L3MBTL1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL917265 | 0.83 | MEN1 (0.40) | L3MBTL1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL915624 | 0.82 | PRKCA (0.42) | L3MBTL1KMT2ACNR1UTS2RHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | ARBOR PHARMACEUTICALS, LLC (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | ARBOR PHARMACEUTICALS, LLC | 2018-09-13 | — | — | US | disclosed |
| US-9944592-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-1660440-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | XENOPORT, INC. | 2009-09-17 | — | — | US | disclosed |
| US-7572830-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7300956-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-7109239-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | XENOPORT, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385014-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | L3MBTL1 1535/4885NPC1 1362/4885CYP1A2 585/4885 |
| US-20180258032-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | L3MBTL1 1535/4885NPC1 1362/4885CYP1A2 585/4885 |
| US-20080096960-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | L3MBTL1 1535/4885NPC1 1362/4885CYP1A2 585/4885 |
| US-20070054945-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | L3MBTL1 1535/4885NPC1 1362/4885CYP1A2 585/4885 |
| US-20090234138-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS | APEH, ABAT, GABARAPL1 | L3MBTL1 1425/4885NPC1 1052/4885CYP1A2 770/4885 |
| US-20110021571-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE | APEH, ABAT, SI | L3MBTL1 1535/4885NPC1 1362/4885CYP1A2 585/4885 |
| US-20050107334-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use | APEH, ABAT, SI | L3MBTL1 1535/4885NPC1 1362/4885CYP1A2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.